Tan Ke, Fan Yi-xiang, Miao Jing-xia, Lü Cheng-wei, Yan Xiao, Luo Rong-cheng
Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2006 Feb;26(2):234-6.
To observe the killing effect of Herceptin and adriamycin sequentially applied on breast cancer cell line in vitro.
BT-474 human breast cancer cells in exponential growth phase were treated with Herceptin alone, adriamycin alone and their sequential administration (Herceptin before adriamycin and vice versa), respectively. Under optical microscope, the morphological changes of the cells were observed before and after drug administration. The expression rate and mean fluorescence intensity (MFI) of HER-2/neu and cell death rate were detected by flow cytometry.
Microscopically, the cells treated with different protocols all exhibited such changes as darkening and increase of cellular debris with irregular cell morphology. Flow cytometry revealed no significant difference in the expression rate of HER-2/neu in each group before and after treatment, but the MFI of HER-2/neu and death rate of the treated cells were significant different from those of the control group (P<0.05). The cell death rate of Herceptin-pretreated cells was significantly higher than that of adriamycin-pretreated ones (P<0.05).
Herceptin pretreatment enhances the killing effect of adriamycin on breast cancer cell line BT-474, which provides experimental evidence for designing clinical sequential biochemotherapy of breast cancer.
观察赫赛汀与阿霉素序贯应用对乳腺癌细胞系的体外杀伤作用。
将处于指数生长期的BT - 474人乳腺癌细胞分别用单独的赫赛汀、单独的阿霉素及其序贯给药(先赫赛汀后阿霉素及先阿霉素后赫赛汀)进行处理。给药前后在光学显微镜下观察细胞的形态变化。采用流式细胞术检测HER - 2/neu的表达率、平均荧光强度(MFI)及细胞死亡率。
显微镜下,不同处理组的细胞均呈现细胞变暗、细胞碎片增多及细胞形态不规则等变化。流式细胞术显示,各组处理前后HER - 2/neu的表达率无显著差异,但处理后细胞的HER - 2/neu的MFI及死亡率与对照组相比有显著差异(P<0.05)。赫赛汀预处理组的细胞死亡率显著高于阿霉素预处理组(P<0.05)。
赫赛汀预处理可增强阿霉素对乳腺癌细胞系BT - 474的杀伤作用,为乳腺癌临床序贯生物化疗方案的设计提供了实验依据。